Literature DB >> 32486903

Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Vera Kim1,2, Thijs van der Wal2, Miriam Yumie Nishi3, Luciana Ribeiro Montenegro3, Flair Jose Carrilho1, Yujin Hoshida2,4, Suzane Kioko Ono1.   

Abstract

Background & aim: Genetic variability in drug absorption, distribution, metabolism and excretion (ADME) genes contributes to the high heterogeneity of drug responses. The present study investigated polymorphisms of ADME genes frequencies and compared the findings with populations from other continents, available in the 1000 Genome Project (1 KGP) and the Exome Aggregation Consortium (ExAC) databases. Methodology & results: We conducted a study of 100 patients in Brazil and a total of 2003 SNPs were evaluated by targeted next-generation sequencing in 148 genes, including Phase I enzymes (n = 50), Phase II enzymes (n = 38) and drug transporters (n = 60). Overall, the distribution of minor allele frequency (MAF) suggests that the distribution of 2003 SNPs is similar between Brazilian cohort, 1 KGP and ExAC; however, we found moderate SNP allele-frequency divergence between Brazilian cohort and both 1000 KGP and ExAC. These differences were observed in several relevant genes including CYP3A4, NAT2 and SLCO1B1.
Conclusion:  We concluded that the Brazilian population needs clinical assessment of drug treatment based on individual genotype rather than ethnicity.

Entities:  

Keywords:  ADME genes; Brazilian; admixture population; genetic diversity; next-generation sequencing; pharmacogenomics

Mesh:

Substances:

Year:  2020        PMID: 32486903      PMCID: PMC7362932          DOI: 10.2217/pgs-2020-0013

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  62 in total

1.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Authors:  D Dai; D C Zeldin; J A Blaisdell; B Chanas; S J Coulter; B I Ghanayem; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-10

2.  Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative.

Authors:  Fernanda Rodrigues-Soares; Fernanda S G Kehdy; Julia Sampaio-Coelho; Poliana X C Andrade; Carolina Céspedes-Garro; Camila Zolini; Marla M Aquino; Mauricio L Barreto; Bernardo L Horta; Maria Fernanda Lima-Costa; Alexandre C Pereira; Adrián LLerena; Eduardo Tarazona-Santos
Journal:  Pharmacogenomics J       Date:  2018-05-01       Impact factor: 3.550

3.  ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.

Authors:  Jian Qu; Bo-Ting Zhou; Ji-Ye Yin; Xiao-Jing Xu; Ying-Chun Zhao; Guang-Hua Lei; Qiang Tang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2012-05-28       Impact factor: 5.243

4.  Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

Authors:  Hyeong-Seok Lim; Han Ju Lee; Keun Seok Lee; Eun Sook Lee; In-Jin Jang; Jungsil Ro
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

5.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

Authors:  S M De Morais; G R Wilkinson; J Blaisdell; U A Meyer; K Nakamura; J A Goldstein
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

6.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

Authors:  S M de Morais; G R Wilkinson; J Blaisdell; K Nakamura; U A Meyer; J A Goldstein
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

7.  Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.

Authors:  Kyung-Hun Lee; Hye Jung Chang; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Yung-Jue Bang; Sun Young Kim; Keun-Wook Lee; Jee Hyun Kim; Yong Sang Hong; Tae Won Kim; Young Suk Park; Won Ki Kang; Sang Joon Shin; Joong Bae Ahn; Gyeong Hoon Kang; Seung-Yong Jeong; Kyu Joo Park; Jae-Gahb Park; Tae-You Kim
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-13       Impact factor: 3.333

8.  Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.

Authors:  Albert-Jan L H J Aarnoudse; Jeanne P Dieleman; Loes E Visser; Pascal P Arp; Ilse P van der Heiden; Ron H N van Schaik; Mariam Molokhia; Albert Hofman; André G Uitterlinden; Bruno H Ch Stricker
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

9.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  1 in total

1.  Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.

Authors:  Rafaela Pirolli; Viviane Teixeira Loiola de Alencar; Felipe Leonardo Estati; Adriana Regina Gonçalves Ribeiro; Daniella Yumi Tsuji Honda; Mariana de Oliveira; Joao Paulo da Silveira Nogueira Lima; Elizabeth Santana Dos Santos; Andrea Paiva Gadelha Guimarães; Glauco Baiocchi; Alexandre André Balieiro Anastácio da Costa
Journal:  BMC Cancer       Date:  2021-05-08       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.